Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Crossing Boundaries III forum on health systems research got off to an exciting start with a good number of guests in attendance. The two-day forum provided useful insights in ongoing research in low and middle income countries. Some of the topics discussed were on were on task shifting, interdisciplinary research methods, antimicrobial resistance, mental health and governance amongst others.

Attendees in a talk

The crossing boundaries III forum on health systems research at the Green Templeton College in Oxford, got off to an exciting start with a good number of guests in attendance. The two - day results dissemination and sharing forum provided useful insights and inputs in ongoing research in low and middle income countries. These studies have the potential impact of improving care for sick newborns and neonates and latest findings from the HSD-N research programme, identified current coverage and gaps in the care of newborns/neonatal services in Kenya.

The project is led by Professor Mike English and Dr Georgina Murphy via the KemriWellcome Trust in Nairobi and from their base at Nuffied Department of Medicine and the University of Oxford. Findings from this meeting focused on and the role of nursing in neonatal care provision, gaps in nursing numbers and potential solutions. Topics discussed were on task shifting, interdisciplinary research methods, antimicrobial resistance, mental health and governance amongst others. The two-day meeting was from the 4-5th of December 2017.

Similar stories

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.